Pediatrics

Q119. Discuss Pediatric Fluid Therapy: the Holliday-Segar maintenance method, the shift to isotonic maintenance fluids, and deficit replacement principles.

Holliday-Segar Method

A commonly-used hourly equivalent, the "4-2-1 rule": 4 mL/kg/hr (first 10 kg), 2 mL/kg/hr (next 10 kg), 1 mL/kg/hr (each kg thereafter).

This weight-based tiered approach reflects that fluid requirements correlate more closely with metabolic rate than body weight in a simple linear fashion, and metabolic rate itself scales in a similarly tiered, non-linear fashion (larger children/adults having proportionally lower metabolic rate per kg than smaller infants).

Modern Isotonic Maintenance Fluid Recommendations – An Important Shift

Historical practice commonly used hypotonic maintenance fluids (e.g., 0.18% or 0.45% saline with dextrose). Accumulated evidence, including several large randomized trials, has demonstrated significantly increased risk of hospital-acquired hyponatremia with hypotonic fluid use, particularly with non-osmotic ADH release (common in acute illness — pain, nausea, stress, certain respiratory/CNS conditions).

Deficit Replacement Calculation

Deficit volume = estimated percentage dehydration × body weight, typically replaced over 24 hours for isotonic/hypotonic dehydration (hypernatremic dehydration requires a notably more prolonged, gradual correction period given cerebral edema risk). Deficit replacement is added to, not substituted for, ongoing maintenance requirements.

Electrolyte Monitoring

Regular serum electrolyte monitoring is essential and non-negotiable during active deficit correction, prolonged IV fluid therapy, and in children at risk for non-osmotic ADH release or underlying renal/cardiac dysfunction — allowing timely identification of emerging derangement and prompt fluid prescription adjustment.

Q120. Discuss Alport Syndrome and Thin Basement Membrane Disease: genetics of Type IV collagen, clinical triad, and electron microscopy findings.

Genetics of Type IV Collagen

Alport syndrome results from mutations in genes encoding alpha chains of Type IV collagen — most commonly COL4A5 (X-linked, the most common pattern — affected males more severe, heterozygous female carriers variable/generally milder), or, less commonly, COL4A3 or COL4A4 (autosomal recessive or dominant patterns). Type IV collagen is a critical structural component of the glomerular basement membrane, also present in the cochlea and lens/ocular basement membranes — directly explaining the multi-system clinical triad.

Clinical Triad

• Hematuria — persistent microscopic hematuria from early childhood, with episodic gross hematuria (often with intercurrent illness); the earliest, most consistent manifestation
• Sensorineural hearing loss — typically bilateral, progressive, characteristically affecting high-frequency sounds initially, developing over childhood/adolescence; absent in thin basement membrane disease
• Ocular abnormalities — most classically anterior lenticonus (conical protrusion of anterior lens surface, relatively specific to Alport), plus characteristic perimacular retinal flecking

Progression and Prognosis

Alport syndrome, particularly in affected males with X-linked disease, characteristically shows progressive decline in renal function, typically progressing to end-stage renal disease by early-to-mid adulthood.

Electron Microscopy Findings – Key Distinguishing Feature

Alport syndrome shows a characteristic "basket-weave" pattern — glomerular basement membrane thickening, splitting, and lamellation — considered diagnostic in the appropriate clinical context.

Q121. Discuss Renal Vein Thrombosis in Neonates: risk factors, the classic clinical triad, diagnosis, and anticoagulation approach.

Risk Factors

Occurs predominantly with a combination of predisposing factors reflecting the neonate's prothrombotic physiology combined with specific exposures:

• Infant of a diabetic mother — a classic, well-recognized association (relative polycythemia/hyperviscosity and other metabolic factors)
• Significant dehydration — hemoconcentration and relative hyperviscosity
• Central venous catheters (particularly umbilical venous catheters) — can directly predispose to thrombosis extending to the renal vein
• Additional factors: sepsis, perinatal asphyxia, underlying inherited thrombophilia

Classic Triad

• Flank mass — the acutely enlarged, congested, thrombosed kidney, often palpable
• Hematuria — typically gross, visible, reflecting acute venous congestion and microvascular injury
• Thrombocytopenia — platelet consumption within the acute thrombotic process

Diagnosis

Doppler ultrasound is the primary, first-line imaging modality — demonstrating an enlarged, echogenic affected kidney with characteristic absent or reversed venous flow on Doppler, along with assessment of thrombus extent (unilateral vs bilateral, and any extension into the inferior vena cava).

Anticoagulation Therapy

Management is individualized based on extent/severity:

• Unilateral RVT without IVC extension, particularly in a stable infant — sometimes managed with supportive care alone (fluid management/hydration, close monitoring) without formal anticoagulation, given the favorable natural history and neonatal bleeding risks
• More extensive disease (bilateral, IVC extension, significant/worsening renal impairment) — generally warrants anticoagulation, typically low molecular weight heparin (more predictable pharmacokinetics, easier monitoring), though unfractionated heparin retains a role where rapid reversibility might be needed

Risk Stratification — A Multi-Layered, Integrated Framework

Chemotherapy Phases

CAR-T Cell Therapy — A Transformative Recent Advance

Tisagenlecleucel (targets CD19) — patient's own T-cells harvested, engineered to express a CD19-targeting chimeric receptor, expanded, and reinfused — for relapsed/refractory B-ALL.

Etiological Classification

Diagnostic Criteria

Severe aplastic anemia: bone marrow hypocellularity (<25%) + peripheral cytopenia meeting severity thresholds in ≥2 of 3 lineages (neutrophils, platelets, reticulocytes), after marrow exam excludes leukemia/MDS.

Treatment Pathways

Pathophysiology

Absent/reduced beta-globin synthesis → unpaired alpha-globin chains precipitate in erythroid precursors → ineffective erythropoiesis + peripheral hemolysis → severe chronic anemia → marrow expansion (“chipmunk facies”, pathological fractures) + extramedullary hematopoiesis (hepatosplenomegaly).

Transfusion Protocols

Regular lifelong transfusion targeting pre-transfusion Hb ≥9–9.5 g/dL (post-transfusion ~13–14 g/dL), every 2–4 weeks, using leukodepleted red cell concentrates. Higher threshold better suppresses marrow expansion, improves growth/skeletal outcomes.

Iron Overload — The Central Long-Term Management Challenge

No active iron excretion mechanism → progressive cumulative overload — deposits in heart (cardiomyopathy, historically leading cause of death), liver (fibrosis/cirrhosis), endocrine organs (growth failure, delayed puberty, diabetes, hypothyroidism, hypoparathyroidism).

Monitoring — MRI T2* as the Central Modern Tool

Oral Iron Chelators

Curative Options

Pathophysiology of Vaso-Occlusive Crisis (VOC)

Point mutation in beta-globin → HbS → polymerizes when deoxygenated → rigid sickle-shaped cells → microvascular occlusion + tissue ischemia. Amplified by chronic hemolysis-associated endothelial dysfunction (↓ nitric oxide bioavailability), increased inflammatory adhesion, and hypercoagulability — a multifactorial vaso-occlusive AND inflammatory process.

Acute Chest Syndrome

New pulmonary infiltrate + respiratory symptoms, from pulmonary vaso-occlusion/infarction + fat embolism (marrow infarction) + infection. Management: oxygen, incentive spirometry, empirical antibiotics, and exchange transfusion for significant/worsening cases (reduces circulating HbS fraction more effectively than simple top-up).

Stroke Prevention — Transcranial Doppler (TCD) Screening

Hydroxyurea Therapy

Primary disease-modifying pharmacotherapy — induces fetal hemoglobin (HbF) production (doesn't participate in HbS polymerization) + improves red cell hydration, reduces leukocyte adhesion, improves NO bioavailability. Reduces VOC frequency, ACS incidence, transfusion needs. Current guidance recommends initiation from as early as 9 months for severe genotypes (HbSS, HbS-β0-thalassemia).

Pneumococcal Prophylaxis

Functional asplenia (progressive splenic infarction) → substantially elevated risk of overwhelming encapsulated organism infection (S. pneumoniae). Penicillin prophylaxis from 2–3 months of age through at least age 5 years, plus complete pneumococcal/encapsulated organism vaccination.

Pathophysiology of Vaso-Occlusive Crisis (VOC)

Point mutation in beta-globin → HbS → polymerizes when deoxygenated → rigid sickle-shaped cells → microvascular occlusion + tissue ischemia. Amplified by chronic hemolysis-associated endothelial dysfunction (↓ nitric oxide bioavailability), increased inflammatory adhesion, and hypercoagulability — a multifactorial vaso-occlusive AND inflammatory process.

Acute Chest Syndrome

New pulmonary infiltrate + respiratory symptoms, from pulmonary vaso-occlusion/infarction + fat embolism (marrow infarction) + infection. Management: oxygen, incentive spirometry, empirical antibiotics, and exchange transfusion for significant/worsening cases (reduces circulating HbS fraction more effectively than simple top-up).

Stroke Prevention — Transcranial Doppler (TCD) Screening

Hydroxyurea Therapy

Primary disease-modifying pharmacotherapy — induces fetal hemoglobin (HbF) production (doesn't participate in HbS polymerization) + improves red cell hydration, reduces leukocyte adhesion, improves NO bioavailability. Reduces VOC frequency, ACS incidence, transfusion needs. Current guidance recommends initiation from as early as 9 months for severe genotypes (HbSS, HbS-β0-thalassemia).

Pneumococcal Prophylaxis

Functional asplenia (progressive splenic infarction) → substantially elevated risk of overwhelming encapsulated organism infection (S. pneumoniae). Penicillin prophylaxis from 2–3 months of age through at least age 5 years, plus complete pneumococcal/encapsulated organism vaccination.

Clinical Severity Classification

Acute Bleeding Management — Factor Concentrate Calculation

Target levels individualized to site/severity (e.g., joint bleed ~40–50%; life-threatening CNS bleed ~100% correction).

Prophylaxis Regimens

Regular scheduled factor infusion (factor VIII: 2–3×/week; factor IX: less frequent) is now standard-of-care for severe hemophilia — reduces spontaneous bleeding AND prevents cumulative hemophilic arthropathy — a shift from reactive to proactive management.

Management of Inhibitors

Updated ASH Guidelines — A Shift Toward Observation

Indications for Treatment

• Significant, active mucocutaneous bleeding (beyond petechiae/bruising)
• Signs suggestive of intracranial or other serious internal bleeding (emergency)
• Urgent invasive procedure planned requiring rapid platelet increase

First-Line Pharmacological Treatment

Management of Chronic/Refractory ITP

ITP persisting >12 months = chronic ITP. TPO receptor agonists — eltrombopag (oral), romiplostim (SC) — stimulate platelet production from megakaryocytes (different mechanism from destruction-focused IVIG/steroids). Increasingly used ahead of splenectomy, given splenectomy's long-term infection risks.